LAP-BAND or medical therapy for metabolic syndrome? Matthew GilbertRichard E. Pratley Clinical Trials Report 02 February 2008 Pages: 5 - 6
Effects of exercise on adipokines and the metabolic syndrome Tongjian YouBarbara J. Nicklas OriginalPaper 02 February 2008 Pages: 7 - 11
Endocannabinoid system overactivity and the metabolic syndrome: Prospects for treatment Jennifer M. PerkinsStephen N. Davis OriginalPaper 02 February 2008 Pages: 12 - 19
Do cardiac and perivascular adipose tissue play a role in atherosclerosis? Gianluca IacobellisYu-Jing GaoArya M. Sharma OriginalPaper 02 February 2008 Pages: 20 - 24
Nonalcoholic fatty liver disease: Diagnosis and relation to metabolic syndrome and approach to treatment Steven D. Lidofsky OriginalPaper 02 February 2008 Pages: 25 - 30
Challenges in developing drugs for the metabolic syndrome Glenn Matfin OriginalPaper 02 February 2008 Pages: 31 - 36
Metabolic syndrome and stroke Amytis TowfighiBruce Ovbiagele OriginalPaper 02 February 2008 Pages: 37 - 41
The metabolic syndrome in primary aldosteronism Francesco FalloGiovanni FederspilPaolo Mulatero OriginalPaper 02 February 2008 Pages: 42 - 47
Why is HDL functionally deficient in type 2 diabetes? Anatol KontushM. John Chapman OriginalPaper 02 February 2008 Pages: 51 - 59
Fatty liver, insulin resistance, and dyslipidemia Martin AdielsMarja-Riitta TaskinenJan Borén OriginalPaper 02 February 2008 Pages: 60 - 64
Derangements of intravascular remodeling of lipoproteins in type 2 diabetes mellitus: Consequences for atherosclerosis development Geesje M. Dallinga-ThieRobin P. F. DullaartArie van Tol OriginalPaper 02 February 2008 Pages: 65 - 70
Diabetic dyslipidemia and atherosclerosis: Evidence from clinical trials John A. Farmer OriginalPaper 02 February 2008 Pages: 71 - 77